Delivery Order SPE2DB22D2005-SPE2DB26FJEC8
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Vyvanse 20 mg capsules (100-count units) under a firm fixed-price contract valued at $1,783.60. The contract was competitively awarded with no set-aside designation and is scheduled for completion by August 6, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. This...
- The Defense Logistics Agency awarded a delivery order valued at $4,459.00 to AmerisourceBergen Drug Corp for the supply of Vyvanse 20 mg capsules (100-count units). This competitively awarded, non-set-aside contract employs firm fixed pricing and carries an ultimate completion date of April 22, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, is fulfilling this order from its corporate office location. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Vyvanse 60 mg capsules (100-count units) under a firm fixed-price contract valued at $1,927.86. The order was competitively awarded without set-aside designation and is scheduled for completion by July 31, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform work at its corporate office location and serve as the prime contractor on this delivery order, which...
- The Defense Logistics Agency awarded a delivery order valued at $17,194.58 to AmerisourceBergen Drug Corp for the supply of Vyvanse 20 mg capsules (100-count units) under a firm fixed price contract. The order, awarded on September 26, 2025, with an ultimate completion date of September 29, 2025, represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is fulfilling this requirement through its corporate office and will perform all...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 15, 2025, for the supply of Vyvanse 30 mg capsules (quantity 100) with a contract value of $1,163.08. This is a firm fixed price delivery order with an ultimate completion date of July 16, 2025, and represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse 10 mg capsules (100-count units) on June 3, 2025, with a ceiling value of $1,823.23 and ultimate completion date of June 4, 2025. This firm fixed-price delivery order represents a non-competitive set-aside contract awarded through open competition. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfills the place of performance requirement...
- The Defense Logistics Agency awarded a firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Vyvanse 30 mg capsules (100-count units) with a ceiling value of $2,943.88. This is a non-set-aside competitive award with a place of performance in Conshohocken, Pennsylvania, and an ultimate completion date of August 7, 2025. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse 50 mg capsules (100-count units) valued at $1,876.30 under a firm fixed price contract type. The award, issued on July 31, 2025, with an ultimate completion date of August 1, 2025, represents a non-competitive delivery order executed against AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Vyvanse 60 mg capsules (100-count units) under a firm fixed-price contract valued at $1,143.98. The delivery order, issued on August 1, 2025, with an ultimate completion date of August 4, 2025, represents a non-competitive award to the prime contractor. Performance will be executed from AmerisourceBergen's location in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a $1,754.54 firm fixed price delivery order to AmerisourceBergen Drug Corp for Vyvanse 30 mg capsules (100 count) on July 14, 2025, with an ultimate completion date of July 15, 2025. This non-set-aside contract represents a single delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The place of performance is...
- SPE2DB22D2005Indefinite Delivery Contract
- SPE2DB22D2005-SPE2DB26FJEC8Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse 20 mg capsules (100-count units) under a firm fixed-price contract valued at $1,783.60. The order was competitively awarded without set-aside designation and carries an ultimate completion date of October 22, 2025. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this delivery order from its corporate office location in the same municipality. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of medications, vaccines, and medical supplies to military healthcare programs worldwide. The Vyvanse delivery—a prescription medication commonly used to treat attention deficit hyperactivity disorder—represents one of numerous pharmaceutical fulfillments under this expansive contract vehicle supporting Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 10/21/25 |